biopharmadive.com /3 weeks ago

Artiva to quit autoimmune cell therapy work, cut staff after patient deaths

The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.

Read source
biopharmadive.com /1 month ago

ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’

Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.

Read source
medcitynews.com /3 weeks ago

Patient Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics attributed one of the fatalities to a drug used to prepare patients for cell therapy and not to the cell therapy itself. But Artiva’s setbacks follow safety...

Read source
newswire.com /1 month ago

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Figh...

Read source
genengnews.com /3 weeks ago

Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die

In announcing the layoffs and strategic alternatives review, Artiva disclosed that two patients in the trial who underwent the study treatment died in Grade 5 safety events. One pa...

Read source
qchron.com /1 month ago

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic An...

SHANGHAI, Oct. 17, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of Beijing Grit Biotherapeutics...

Read source
biopharmadive.com /1 month ago

Belgian startup revives Galapagos CAR-T research

Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a s...

Read source
qchron.com /1 week ago

Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ded...

Read source
cafepharma.com /6 days ago

Vera Therapeutics

Vera Therapeutics Anonymous (not verified) Mon, 11/16/2026 - 00:40 field_thread_url https://cafepharma.com/boards/threads/vera-therapeutics.713115/...

Read source
pharmexec.com /2 days ago

<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>

Read source
prweb.com /4 days ago

MABT Appoints Professor Srinivasan Madhusudan to Its Scientific Advisory Board

MABT is a pharmaceutical company focused on the development and commercialization of novel therapeutic approaches and AI-enabled technologies. Our scientific and medical focus is o...

Read source
pharmexec.com /1 week ago

<![CDATA[AstraZeneca Acquires Omniose, Adding Bioconjugation Platform to Vaccine Pipeline]]>

Read source
pharmexec.com /3 weeks ago

<![CDATA[Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acqui...

Read source
newswire.com /6 days ago

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Re...

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy ad...

Read source
orthotw.com /1 month ago

DiFusion to Define Therapeutic Biomaterials Category at NASS 2026

Red Theater presentation will distinguish conventional biotolerable implants from materials deliberately engineered to influence the host response and participate in healing

Read source
cafepharma.com /1 week ago

Averitas

Averitas Anonymous (not verified) Wed, 11/11/2026 - 21:36 field_thread_url https://cafepharma.com/boards/threads/averitas.667825/ board...

Read source
orthospinenews.com /1 month ago

BioLab Holdings Launches EmeraNovaâ„¢ to Advance the Future of Tissue Restoration

Expanded vision reflects focus beyond wound care to advancing innovation across the full tissue restoration journey PHOENIX, October…

Read source
qchron.com /1 month ago

Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential...

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager

Read source
medcitynews.com /1 month ago

TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance

Eli Lilly-partnered TRexBio will apply the IPO proceeds toward clinical development of molecules designed to activate regulatory T cells to mediate immune responses and inflammatio...

Read source
cafepharma.com /1 month ago

Averitas

Averitas Anonymous (not verified) Wed, 10/21/2026 - 13:15 field_thread_url https://cafepharma.com/boards/threads/averitas.667825/ board...

Read source
cafepharma.com /1 week ago

INVIVYD

INVIVYD Anonymous (not verified) Tue, 11/10/2026 - 21:36 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...

Read source
biopharmadive.com /1 month ago

TRex Bio prices $117M IPO to support immune drug work

Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.

Read source
seekingalpha.com /1 week ago

Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program - Slideshow

Read source
pharmexec.com /1 week ago

<![CDATA[argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities ]]>

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.